Cargando…

Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma

BACKGROUND: Fibrolamellar Carcinoma (FLC), a subtype of hepatocellular carcinoma (HCC), is a rare primary hepatic malignancy. Several aspects of the clinic features and epidemiology of FLC remain unclear because most of the literature on FLC consists of case reports and small cases series with limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-Luna, Laura E, Arrieta, Oscar, García-Leiva, Jorge, Martínez, Braulio, Torre, Aldo, Uribe, Misael, León-Rodríguez, Eucario
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1310628/
https://www.ncbi.nlm.nih.gov/pubmed/16259635
http://dx.doi.org/10.1186/1471-2407-5-142
_version_ 1782126318791426048
author Moreno-Luna, Laura E
Arrieta, Oscar
García-Leiva, Jorge
Martínez, Braulio
Torre, Aldo
Uribe, Misael
León-Rodríguez, Eucario
author_facet Moreno-Luna, Laura E
Arrieta, Oscar
García-Leiva, Jorge
Martínez, Braulio
Torre, Aldo
Uribe, Misael
León-Rodríguez, Eucario
author_sort Moreno-Luna, Laura E
collection PubMed
description BACKGROUND: Fibrolamellar Carcinoma (FLC), a subtype of hepatocellular carcinoma (HCC), is a rare primary hepatic malignancy. Several aspects of the clinic features and epidemiology of FLC remain unclear because most of the literature on FLC consists of case reports and small cases series with limited information on factors that affect survival. METHODS: We did a retrospective analysis of the clinical and histological characteristics of FLC. We also determined the rate of cellular proliferation in biopsies of these tumors. We assessed whether these variables were associated with survival. RESULTS: We found 15 patients with FLC out of 174 patients with HCC (8.6%). Between patients with these neoplasms, we found statistically significant survival, age at onset, level of alpha fetoprotein, and an earlier stage of the disease. The 1, 3 and 5 year survival in patients with FLC was of 66, 40 and 26% respectively. The factors associated with a higher survival in patients with FLC were age more than 23 years, feasibility of surgical resection, free surgical borders, absence of thrombosis or invasion to hepatic vessels and the absence of alterations in liver enzymes. The size of the tumor, gender, cellular proliferation and atypia did not affect the prognosis. CONCLUSION: We concluded that FLC patients diagnosed before 23 years of age have worse prognosis than those diagnosed after age 23. Other factors associated with worse prognosis in this study are: lack of surgical treatment, presence of positive surgical margins, vascular invasion, and altered hepatic enzymes.
format Text
id pubmed-1310628
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13106282005-12-10 Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma Moreno-Luna, Laura E Arrieta, Oscar García-Leiva, Jorge Martínez, Braulio Torre, Aldo Uribe, Misael León-Rodríguez, Eucario BMC Cancer Research Article BACKGROUND: Fibrolamellar Carcinoma (FLC), a subtype of hepatocellular carcinoma (HCC), is a rare primary hepatic malignancy. Several aspects of the clinic features and epidemiology of FLC remain unclear because most of the literature on FLC consists of case reports and small cases series with limited information on factors that affect survival. METHODS: We did a retrospective analysis of the clinical and histological characteristics of FLC. We also determined the rate of cellular proliferation in biopsies of these tumors. We assessed whether these variables were associated with survival. RESULTS: We found 15 patients with FLC out of 174 patients with HCC (8.6%). Between patients with these neoplasms, we found statistically significant survival, age at onset, level of alpha fetoprotein, and an earlier stage of the disease. The 1, 3 and 5 year survival in patients with FLC was of 66, 40 and 26% respectively. The factors associated with a higher survival in patients with FLC were age more than 23 years, feasibility of surgical resection, free surgical borders, absence of thrombosis or invasion to hepatic vessels and the absence of alterations in liver enzymes. The size of the tumor, gender, cellular proliferation and atypia did not affect the prognosis. CONCLUSION: We concluded that FLC patients diagnosed before 23 years of age have worse prognosis than those diagnosed after age 23. Other factors associated with worse prognosis in this study are: lack of surgical treatment, presence of positive surgical margins, vascular invasion, and altered hepatic enzymes. BioMed Central 2005-10-31 /pmc/articles/PMC1310628/ /pubmed/16259635 http://dx.doi.org/10.1186/1471-2407-5-142 Text en Copyright © 2005 Moreno-Luna et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Moreno-Luna, Laura E
Arrieta, Oscar
García-Leiva, Jorge
Martínez, Braulio
Torre, Aldo
Uribe, Misael
León-Rodríguez, Eucario
Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
title Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
title_full Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
title_fullStr Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
title_full_unstemmed Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
title_short Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
title_sort clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1310628/
https://www.ncbi.nlm.nih.gov/pubmed/16259635
http://dx.doi.org/10.1186/1471-2407-5-142
work_keys_str_mv AT morenolunalaurae clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma
AT arrietaoscar clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma
AT garcialeivajorge clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma
AT martinezbraulio clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma
AT torrealdo clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma
AT uribemisael clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma
AT leonrodriguezeucario clinicalandpathologicfactorsassociatedwithsurvivalinyoungadultpatientswithfibrolamellarhepatocarcinoma